Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (18524)	4/2/1998 3:36:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Walter, I think that you have to remember that the "L" in CTCL stands for Lymphoma. If you recall, the post that initially appeared on AOL indicated that the poster's mother's life was "saved" because of Targretin. She had tried several other therapies for years and was on a clear southerly course when she started Targretin treatments, which either eliminated or reduced her lesions which covered a significant portion of her body. These are cancer patients and approval is based on a risk-reward formula. Saving a life is reasonably high on the reward side of the equation. As I recall, 90% of the patients treated with oral Targretin had complete remissions, partial remissions, or stabilization of the disease. I would put approval for oral Targretin for CTCL in the same "slam dunk" category as topical Panretin is in for KS.